Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Weight, metabolic improvements with low-carb diet have null effect on cancer progression

25 Jun 2020

Prostate cancer patients with biochemical recurrence (BCR) may benefit from a low-carbohydrate diet (LCD), which leads to weight loss and metabolic improvements, but these effects have no positive impact on tumour growth, as shown in the results of a trial.

The 6-month randomized trial examined the effect of LCD (n=31) vs a no-intervention control (n=26) on prostate-specific antigen (PSA) doubling time (PSADT) in men with prostate cancer with BCR after local treatment. All participants had body mass index (BMI) ≥24 kg/m2 and PSADT of 3–36 months. The LCD arm was instructed to eat 20 g/carbs/day.

The study was discontinued prematurely after an interim analysis showed futility. A total of 27 LCD and 18 control patients completed the study.

At 6 months, both groups had similar intake of protein and fats, although patients in the LCD group had greater reductions in carbohydrates intake (−117 vs 8 g; p<0.001) and in weight (−12.1 vs −0.50 kg; p<0.001). Furthermore, LCD was associated with decreases in high-density lipoprotein cholesterol, triglycerides, and HbA1c, with no difference in total cholesterol or glucose.

The primary outcome of PSADT was comparable between the LCD and control groups (mean, 21 vs 15 months; p=0.316). A posthoc exploratory analysis accounting for prestudy PSADT, baseline PSA, primary treatment, and haemoconcentration showed that the outcome was significantly longer in the LCD group (28 vs 13 months; p=0.021).

Adverse events occurred infrequently, generally mild in severity, and returned to baseline by 6 months.

In light of the exploratory findings of longer PSADT, larger studies testing LCD on disease progression are needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.